SI-BONE (SIBN) Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SIBN shares.
View SIBN analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 1-year price targets for SI-BONE's stock. Their SIBN share price forecasts range from $20.00 to $33.00. On average, they anticipate the company's share price to reach $28.00 in the next twelve months. This suggests a possible upside of 34.7% from the stock's current price.
View analysts price targets for SIBN or view top-rated stocks among Wall Street analysts.

SI-BONE's stock was trading at $13.60 at the beginning of 2023. Since then, SIBN stock has increased by 52.8% and is now trading at $20.78.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our SIBN earnings forecast.

SI-BONE, Inc. (NASDAQ:SIBN) released its quarterly earnings results on Monday, August, 7th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.11. The company had revenue of $33.31 million for the quarter, compared to analyst estimates of $32.24 million. SI-BONE had a negative trailing twelve-month return on equity of 40.35% and a negative net margin of 38.32%.

SI-BONE updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $132.00 million-$134.00 million, compared to the consensus revenue estimate of $130.03 million.

10 employees have rated SI-BONE Chief Executive Officer Jeffrey Dunn on Glassdoor.com. Jeffrey Dunn has an approval rating of 41% among the company's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other SI-BONE investors own include CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), RTX (RTX), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Alibaba Group (BABA), Cisco Systems (CSCO) and CSX (CSX).

(SIBN) raised $84 million in an initial public offering (IPO) on Wednesday, October 17th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

SI-BONE trades on the NASDAQ under the ticker symbol "SIBN."

Shares of SIBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SIBN stock can currently be purchased for approximately $20.78.

SI-BONE (NASDAQ:SIBN) has a market capitalization of $803.98 million and generates $106.41 million in revenue each year. The company earns $-61,260,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis.

The company employs 357 workers across the globe.

SI-BONE's mailing address is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. The official website for the company is www.si-bone.com. The company can be reached via phone at (408) 207-0700 or via email at investors@si-bone.com.